The firm remains on track to file for FDA clearance of its T2Bacteria panel, which its CEO called a "game changer" by mid-2017.
The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
The infectious disease diagnostics firm secured eight new contracts covering 18 hospital in the US and Europe during the fourth quarter.
The infectious disease diagnostics firm will initially receive $40 million from CRG, most of which will go towards paying down existing debt.
It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.
A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
T2 and Allergan will develop a novel diagnostic panel for the detection of Gram-negative bacterial species and antibiotic resistance in patients with bacterial infections.
T2 said it's in a strong position to achieve planned portfolio milestones over the next two years, including submitting its next test for FDA clearance next year.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.